ClinicalTrials.gg
Active, not recruitingNCT05223322DECODEUpdated Jul 14, 2026

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

An interventional study of Taking Charge during Treatment (TCT) Intervention in Breast Cancer, sponsored by Medical College of Wisconsin. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Breast Neoplasms by Medical College of Wisconsin — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Medical College of Wisconsin.

Planned enrollment
6th of 17
80 · median 45
Started
2022
with 1 other
No phase
12 of 23
4 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
14th of 23
by date

Among the 23 studies in Breast Neoplasms by Medical College of Wisconsin, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 14th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 23 studies in Breast Neoplasms by Medical College of Wisconsin are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Breast Neoplasms by Medical College of Wisconsin, or all of them as a file.
02

Study summary

Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). Within the last 10 years technological advancements of -omics approaches, such as RNA-sequencing and shotgun proteomics, have dramatically reduced the cost and technical challenge of accessing these tools for discovery-based research. Investigators are now able to obtain unbiased datasets showing changes in transcript or protein expression within complex samples. With cost and accessibility of sequencing is no longer being substantial bottleneck, one of major challenges researchers now face is determining how to meaningfully interpret profiles from large datasets. The extensive characterization of molecular pathways impacting inflammatory responses, endothelial function and angiogenesis, the pathway and network analysis tools will be an asset for identification molecular pathways relevant to alterations in microvascular endothelial function. The investigators preliminary studies on only a small number of samples highlights this potential of the proposed approach to lead to identify personalized medicine-based profiles that will predict patients are likely to develop microvascular endothelial dysfunction from CTx.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥ 18 years) assigned female sex at birth
  • Diagnosed with invasive non- breast cancer
  • Receiving CTx (or adjuvant CTx and undergoing breast conserving surgery) that includes anthracyclines (such as DOX) and/or targeted anti-Her2 therapy
  • Able to safely participate in moderate exercise and strength training based on MD approval
  • Willing to complete all study activities
  • Self-identifies as Black/African American or non-Hispanic White

Exclusion criteria

Exclusion Criteria:

  • Unintentional weight loss > 10% in the past 6 months
  • Current pregnant and lactating patients. Must have completed lactation prior to study start
  • disease
  • Diagnosed cardiovascular disease as evidenced by cardiomyopathy (reduced regional or global LV contractility), diastolic dysfunction grade 2 or above, symptomatic coronary - artery disease, below 50%
  • History of prior chemotherapy or targeted H2N Treatment received less than 3 years ago
  • Non-English speaking
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Taking Charge during Treatment (TCT) Intervention

    Taking Charge during Treatment (TCT) Intervention. TCT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Participants will receive "Take Charge" program binder, 2-4 x weekly text messaging, activity tracker and resistance bands.

    Behavioral: Taking Charge during Treatment (TCT) Intervention

  • No intervention
    Control Group

    To ensure scientific rigor allowing us to test causal pathways associated with exercise, women will be randomized to the TCT intervention or control group arm. The control group will not receive the TCT intervention The investigators experience teaches us that to increase the likelihood of retaining control group participants, the investigators must offer some resources. Thus, the investigators will provide the control group with a one-page summary of the American College of Sports Medicine exercise recommendations, and the "Take Charge" program binder at the completion of the study. Participants will also receive resistance bands and activity tracker at the end of the study. 95 The investigators will also send weekly text messages with supportive content not related to exercise or lifestyle (i.e., a riddle, "take a moment to smile today," a picture of a baby animal).

Interventions

  • BehavioralTaking Charge during Treatment (TCT) Intervention

    CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.

06

What researchers measure

Primary outcomes

  1. Maximal Exercise: Maximal oxygen consumption will be evaluated using cycle ergometry or treadmill to exhaustion as described in the Integrative Physiology Laboratory at each testing visit.

    Investigators will use a graded protocol, starting at 50 watts followed by 30 watt increments every 2 minutes. Subjects will be connected to a breath-by-breath metabolic system (Cosmed, Italy) for measurement of VO2peak. A maximal effort will be defined as fulfillment of three of the following criteria: 1) A plateau in VO2 with an increase in work rate defined as an increase in VO2 of less than 50 ml/min; 2) A maximal HR within 10 beats of predicted maximal heart rate; 3) A respiratory exchange ratio of greater than 1.15; 4) No increase in heart rate with an increase in work rate (less than 3 beats); or 5) A rating of perceived exertion of 18 or greater on the Borg scale. These criteria are according to and consistent with the AHA exercise testing guidelines and performed regularly in Dr. Phillips' and Dr. Durand's laboratory groups59, 62-66.

    Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12 months)

Secondary outcomes

  1. Functional Assessment of Cancer Therapy - General (FACT-B)

    This survey measures physical, social, emotional, and functional wellbeing and wellness and symptoms associated with breast cancer and its treatments.

    Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12 months)

  2. The Distress Thermometer

    This is a simple tool to effectively screen for symptoms of distress.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  3. Perceived Stress Scale

    This survey is a class stress assessment to help understand how different situations affect feelings and perceived stress, asking about thoughts and feelings.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  4. Hospital Anxiety and Depression Scale

    This will measure anxiety and depression in a general medical population of patients.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  5. The Functional Assessment of Chronic Illness Therapy - Fatigue

    Participants will self-report fatigue and its impact upon daily activities and function.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  6. PROMIS - Social Support

    This survey will assess how much social support each individual has in their personal network.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12 months)

  7. PROMIS - Pain Interference

    This instrument will measure the self-reported consequences of pain on relevant aspects of a person's life.

    Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12-15 months)

  8. Assess mitochondrial DNA damage

    Mitochondrial DNA damage will be assessed in isolated vessels from biopsies and total peripheral blood mononuclear blood cells (PBMCs) via a well-established PCR protocol. Similarly, a PCR based method is used to quantify levels of cell free mtDNA in plasma samples from study participants.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  9. Cytokine analysis

    Investigators will utilize Isoplex platform via CodePlex Human Cytokine Storm Panel-8 to quantify a large array of inflammatory cytokines using minimal amounts (\<30 ul) of plasma sample.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  10. Gene Express Profiling

    Transcriptomic expression profiling of PBMC and endothelial cells will be performed utilizing existing infrastructure (Genomic Sciences and Precision Medicine Center at MCW). RNA sequencing will be performed Illumina on NovaSeq sequencer.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (115 months)

  11. Endothelial function

    Microvascular function from gluteal and surgical fat biopsies will be used to test the direct effect of clinically used chemotherapy on peripheral microvascular function (as surrogate for coronary microvessels). Investigators propose to perform studies before, after the chemotherapy regimen, and at 12 months follow up. Study team evaluate microvascular dilator capacity, both endothelial and smooth muscle mediated, and quantify levels of vasodilators (NO and H2O2) via fluorescent probes.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  12. Flow Mediated Dilation

    Flow mediated dilation of the brachial artery (large conduit vessels) will be assessed using ultrasound in a noninvasive manner.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12 months)

  13. Cardiac function - Echocardiagram

    Echocardiograms: Aortic diameter, cardiac output, stroke volume, heart rate, end diastolic, and end systolic volume will be assessed at rest using two-dimensional echocardiography. With subjects in the left lateral position, measurements will be obtained using the two (Parasternal and Short Axis) and four-chamber view.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  14. Cardiac function - Pulse Wave Velocity

    Pulse Wave Velocity: A non-invasive technique will be used to measure arterial stiffness (pulse wave velocity and central pressures). Briefly, investigators will record waveforms at the carotid and femoral arteries using tonometry and a partially inflated pressure cuff placed over the upper arm and thigh. The distance between sites will be determined using a tape measure.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  15. Cognitive Function

    PROMIS - Cognitive Function Short Form: This is a short six-item sub-set scale of the full PROMIS Cognitive Function item bank that assesses patient-perceived cognitive deficits

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

Other outcomes

  1. DEXA Scan

    Body composition: DXA imaging is a 10 minute, noninvasive, technique that provides precise whole-body measurements of fat (total and visceral) and lean mass. Certified DXA technologists will perform and analyze whole body measures using the same machine for each participant at each time point. To ensure reliability and precision, machines are calibrated daily.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  2. Height and Weight

    Height and Weight: To calculate BMI, investigators will will assess height (baseline only) using a portable stadiometer and weight using a digital scale with participants wearing light clothes and no shoes. A 0.2 kg discrepancy in weight or a 0.5 cm discrepancy in height in the first two measurements, will result in a third measurement.

    Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12-15 months)

  3. Accelerometry

    Accelerometry. Summary measures of PA levels will be derived from 7-day accelerometer wear data (% time sedentary, % time moderate to vigorous PA, counts per minute). Study team will adopt the common guideline of 10 hours or more of wear time necessary to define a valid day. Investigators will use the Troiano cut points (sedentary, light, moderate, vigorous).

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  4. Physical Activity self report

    Godin Leisure Activity Index collects data on mild, moderate, and vigorous activity.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  5. Pittsburgh Sleep Quality Index

    This is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  6. Sitting Time Questionnaire

    The STQ is a 5-question self-report survey asking about amount of time spent sedentary.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  7. Handgrip strength

    Measured with a Takei handgrip dynamometer. This test of LM function correlates with total body muscle strength73 and mortality74.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  8. Sit to Stand

    Number of completed Sit to Stand repetitions performed in 30 secs using a chair with no arms with a height of approximately 43 cm75.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

  9. 6 Minute Walk Test

    Total distance traveled in 6 mins is recorded and used to determine endurance.

    Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 57 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Feb 3, 2022
StartActual
Mar 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05223322
Responsible party
Melinda Stolley (Professor, Medical College of Wisconsin) — Principal investigator
First posted
Feb 3, 2022
Start date
Mar 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion